Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gallium maltolate in refractory malignancies
NCT00050687Phase 2Terminated
- Sponsor
- Titan Pharmaceuticals, Inc.
- Start
- Jun 2001
- Primary completion
- Mar 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of gallium maltolate in prostate cancer (PCa), multiple myeloma (MM), bladder cancer and 1 more, sponsored by Titan Pharmaceuticals, Inc. Primary endpoints: Adverse Effects and Serum Concentrations of Gallium. Started Jun 2001; status: terminated.
02
Drugs
gallium maltolate
03
Conditions
prostate cancer (PCa)multiple myeloma (MM)bladder cancerlymphoma
Beyond the preview
Go deeper on NCT00050687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00050687.